AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint...
Hence then, the article about successful extension of nucleic acid aptamer pharmacokinetics in joint research by ajinomoto co inc and ribomic inc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. )
Also on site :
- UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
- Scott Ritter say he was ‘de-banked’
- AI boom fuels fears of an industry bubble (VIDEO)